CBLB

CBLB

CBLB Molekülinformation

Molecule Name
E3 ubiquitin-protein ligase CBL-B
Molekülalias
CBL-B,CBLB,RNF56
Drug Development Progress
Anzahl der klinischen Arzneimittel3
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence B,Casitas B-lineage lymphoma proto-oncogene b,RING-type E3 ubiquitin transferase CBL-B,SH3-binding protein CBL-B,RING finger protein 56,Nbla00127,RNF56,Signal transduction protein CBL-B,Cas-Br-M (Murine) Ectropic Retroviral Transforming Sequence B,Cbl Proto-Oncogene, E3 Ubiquitin Protein Ligase B,Cbl Proto-Oncogene B,Cbl Proto-Oncogene B, E3 Ubiquitin Protein Ligase,Cbl-B
Molekülhintergrund
Casitas B-lineage lymphoma proto-oncogene b (CBLB) is also known as RNF56. E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. Expressed in placenta, heart, lung, kidney, spleen, ovary and testis, as well as fetal brain and liver and hematopoietic cell lines, but not in adult brain, liver, pancreas, salivary gland, or skeletal muscle.

CBLB Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
HST-1011HST-1011; HST1011Phase 2 ClinicalHotSpot Therapeutics Inc
Neoplasms; Solid tumours
Details
APN-401APN-401Phase 1 ClinicalApeiron Biologics
Brain metastases; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours
Details
NX-1607NX-1607Phase 1 ClinicalNurix Therapeutics Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Mesothelioma; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Richter's Syndrome; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details